In our study, we reviewed 2813 stage I patients including 126 adenocarcinomas with TTF-1+ and 2687 adenocarcinomas with TTF-1− to have a comprehensive understanding of the clinicopathologic features, patterns of recurrence, chemotherapeutic efficacy and the prognosis associated with TTF-1 expression. Here, TTF1 is linked to adenocarcinoma.